Could a gentler chemo combo with delayed immunotherapy tame advanced lung cancer?

NCT ID NCT07647094

Recruiting now Disease control Sponsor: People's Hospital of Quzhou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a standard-dose version in about 112 adults with advanced or metastatic disease. The goal is to see if the lower-dose approach can control the cancer while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Serplulimab, Nab-Paclitaxel, Carboplatin
What this could lead to: If successful, this could offer a less toxic first-line treatment option for advanced squamous lung cancer, potentially improving quality of life while controlling the disease.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not be conclusive. Lower doses might reduce side effects but could also be less effective at controlling the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Quzhou people's Hospital
RECRUITING

Quzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.